Lataa...
Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosi...
Tallennettuna:
| Julkaisussa: | Br J Clin Pharmacol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6533422/ https://ncbi.nlm.nih.gov/pubmed/30335197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13791 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|